Last reviewed · How we verify
Bovizole (THIABENDAZOLE)
At a glance
| Generic name | THIABENDAZOLE |
|---|---|
| Drug class | Anthelmintic |
| Target | Cytochrome P450 1A2 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1967 |
Approved indications
- Ancylostoma Duodenale Infection
- Ascariasis
- Cutaneous larva migrans
- Enterobiasis
- Infection by Strongyloides
- Infection by Uncinaria
- Infection by larvae of Trichinella spiralis
- Infection due to Toxocara
- Necator Americanus Infection
- Trichuriasis
Common side effects
Key clinical trials
- Immersive Virtual Reality Training for Improving Cognition in Adults With Metabolic Syndrome (NA)
- Digital Multimodal Rehabilitation for People With Post-acute COVID-19 Syndrome. (NA)
- Immersive Virtual Reality Techniques on the Effects on Cognition in People With Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bovizole CI brief — competitive landscape report
- Bovizole updates RSS · CI watch RSS